Clinical outcomes within 1-year following LVAD implantation, for the entire cohort and the dichotomized cohort based on their preoperative MELD score
| . | All patients . | MELD <12.6 . | MELD ≥12.6 . | P-value . |
|---|---|---|---|---|
| Follow-up time (days), median (IQR) | 401 (695) | 533 (755) | 264 (661) | 0.001 |
| RVAD after LVAD, n (%) | 15 (6) | 4 (4) | 11 (6) | 0.453 |
| Neurologic event,an (%) | 38 (13) | 7 (7) | 31 (16) | 0.035 |
| Confirmed pump thrombosis, n (%) | 2 (1) | 0 | 2 (1) | 0.538 |
| Re-explorations post-LVAD, n (%) | 110 (38) | 31 (32) | 79 (47) | 0.024 |
| Transplantation, n (%) | 41 (14) | 13 (13) | 28 (15) | 0.799 |
| . | All patients . | MELD <12.6 . | MELD ≥12.6 . | P-value . |
|---|---|---|---|---|
| Follow-up time (days), median (IQR) | 401 (695) | 533 (755) | 264 (661) | 0.001 |
| RVAD after LVAD, n (%) | 15 (6) | 4 (4) | 11 (6) | 0.453 |
| Neurologic event,an (%) | 38 (13) | 7 (7) | 31 (16) | 0.035 |
| Confirmed pump thrombosis, n (%) | 2 (1) | 0 | 2 (1) | 0.538 |
| Re-explorations post-LVAD, n (%) | 110 (38) | 31 (32) | 79 (47) | 0.024 |
| Transplantation, n (%) | 41 (14) | 13 (13) | 28 (15) | 0.799 |
Ischaemic or haemorrhagic.
IQR: interquartile range; LVAD: left ventricular assist device; MELD: Model for End-stage Liver Disease; RVAD: right ventricular assist device.
Clinical outcomes within 1-year following LVAD implantation, for the entire cohort and the dichotomized cohort based on their preoperative MELD score
| . | All patients . | MELD <12.6 . | MELD ≥12.6 . | P-value . |
|---|---|---|---|---|
| Follow-up time (days), median (IQR) | 401 (695) | 533 (755) | 264 (661) | 0.001 |
| RVAD after LVAD, n (%) | 15 (6) | 4 (4) | 11 (6) | 0.453 |
| Neurologic event,an (%) | 38 (13) | 7 (7) | 31 (16) | 0.035 |
| Confirmed pump thrombosis, n (%) | 2 (1) | 0 | 2 (1) | 0.538 |
| Re-explorations post-LVAD, n (%) | 110 (38) | 31 (32) | 79 (47) | 0.024 |
| Transplantation, n (%) | 41 (14) | 13 (13) | 28 (15) | 0.799 |
| . | All patients . | MELD <12.6 . | MELD ≥12.6 . | P-value . |
|---|---|---|---|---|
| Follow-up time (days), median (IQR) | 401 (695) | 533 (755) | 264 (661) | 0.001 |
| RVAD after LVAD, n (%) | 15 (6) | 4 (4) | 11 (6) | 0.453 |
| Neurologic event,an (%) | 38 (13) | 7 (7) | 31 (16) | 0.035 |
| Confirmed pump thrombosis, n (%) | 2 (1) | 0 | 2 (1) | 0.538 |
| Re-explorations post-LVAD, n (%) | 110 (38) | 31 (32) | 79 (47) | 0.024 |
| Transplantation, n (%) | 41 (14) | 13 (13) | 28 (15) | 0.799 |
Ischaemic or haemorrhagic.
IQR: interquartile range; LVAD: left ventricular assist device; MELD: Model for End-stage Liver Disease; RVAD: right ventricular assist device.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
